Euroopan unioni - suomi - EMA (European Medicines Agency)

gilead sciences ireland uc - cobicistat - hiv-infektiot - antiviraalit systeemiseen käyttöön - tybost is indicated as a pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily as part of antiretroviral combination therapy in human immunodeficiency virus-1 (hiv-1) infected adults and adolescents aged 12 years and older:weighing at least 35 kg co‑administered with atazanavir orweighing at least 40 kg co‑administered with darunavir.

Euroopan unioni - suomi - EMA (European Medicines Agency)

gilead sciences ireland uc - tenofoviirisalfenamidifumaraatti - b-hepatiitti - antiviraalit systeemiseen käyttöön - vemlidy is indicated for the treatment of chronic hepatitis b (chb) in adults and paediatric patients 6 years of age and older weighing at least 25 kg (see section 5.

Euroopan unioni - suomi - EMA (European Medicines Agency)

gilead sciences ireland uc - sofosbuvir - hepatiitti c, krooninen - antiviraalit systeemiseen käyttöön - sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adult and paediatric patients aged 3 years and above (see sections 4. 2, 4. 4 ja 5. hepatiitti c-virus (hcv) genotyyppi spesifinen aktiivisuus, ks. kohdat 4. 4 ja 5. sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adults and paediatric patients aged 3 years and above (see sections 4. 2, 4. 4 ja 5. hepatiitti c-virus (hcv) genotyyppi spesifinen aktiivisuus, ks. kohdat 4. 4 ja 5.

Euroopan unioni - suomi - EMA (European Medicines Agency)

gilead sciences ireland uc - sofosbuvir, velpatasvir, voxilaprevi - hepatiitti c, krooninen - antiviraalit systeemiseen käyttöön - vosevi is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients aged 12 years and older and weighing at least 30 kg. (ks. kohdat 4. 2, 4. 4 ja 5.

Euroopan unioni - suomi - EMA (European Medicines Agency)

gilead sciences ireland uc - bictegravir, emtrisitabiini, tenofoviiri alafenamide, fumaraatti - hiv-infektiot - antiviraalit systeemiseen käyttöön - biktarvy is indicated for the treatment of human immunodeficiency virus 1 (hiv 1) infection in adults and paediatric patients at least 2 years of age and weighing at least 14 kg i without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. (ks. kohta 5.

Euroopan unioni - suomi - EMA (European Medicines Agency)

gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Euroopan unioni - suomi - EMA (European Medicines Agency)

gilead sciences ireland uc - sacituzumab govitecan - breast neoplasms; triple negative breast neoplasms - antineoplastiset aineet - trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mtnbc) who have received two or more prior systemic therapies, including at least one of them for advanced disease.

Euroopan unioni - suomi - EMA (European Medicines Agency)

gilead sciences ireland unlimited company - lenacapavir sodium - hiv-infektiot - antiviraalit systeemiseen käyttöön - sunlenca injection, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen (see sections 4. 2 ja 5. sunlenca tablet, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen, for oral loading prior to administration of long-acting lenacapavir injection (see sections 4. 2 ja 5.

Euroopan unioni - suomi - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. katso kohdat 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.

Euroopan unioni - suomi - EMA (European Medicines Agency)

gilead sciences ireland uc - emtrisitabiinin, tenofoviiridisoproksiilifumaraatin - hiv-infektiot - antiviraalit systeemiseen käyttöön - treatment of hiv-1 infection: , truvada is indicated in antiretroviral combination therapy for the treatment of hiv-1 infected adults. , truvada on myös indikoitu hiv-1-tartunnan saaneille nuorille, joilla on nrti-resistenssi tai toksisia vaikutuksia ei siten voi käyttää ensimmäisen linjan tekijöille, iältään 12 - < 18 vuotta. , pre-exposure prophylaxis (prep): , truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired hiv-1 infection in adults at high risk.